Overview

A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis

Status:
Completed
Trial end date:
2021-09-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts. Each participant will enroll in one part. The study will last 12 to 24 weeks, depending on part.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company